Sign up
Pharma Capital

Oncimmune receives regulatory approval from Israel for lung cancer diagnosis kit

Lung cancer kills more people in Israel than any other form of the disease, said the company.
Cigarette
Smokers at risk can by identified by Oncimmune

Oncimmune Holdings PLC (LON:ONC) has received regulatory approval to sell its early stage lung cancer detector, EarlyCDT-Lung, in Israel.

Lung cancer kills more people in Israel than any other form of the disease, said the company.

On an age-standardised basis, Israel's lung cancer mortality rate is 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region. 

Adam Hill, chief executive, added that the approval 'paves the way for the near-term commencement of commercial sales of EarlyCDT-Lung in the sophisticated healthcare market of Israel'. 

Oncimmune already has exclusive distribution agreements in numerous countries including Germany, France, Italy and Spain, while approval for an EarlyCDT-Lung kit was recently granted in Singapore.

PhilW.jpg
Why Invest In Oncimmune? Read More Here

Register here to be notified of future ONC Company articles
View full ONC profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.